HRP20100516T1 - Tiazolpirazolopirimidini kao antagonisti receptora crf1 - Google Patents

Tiazolpirazolopirimidini kao antagonisti receptora crf1 Download PDF

Info

Publication number: HRP20100516T1
Authority: HR; Croatia
Prior art keywords: pharmaceutically acceptable; acceptable salt; compound according; morpholin; methyl
Prior art date: 2006-09-20

Application number

HR20100516T

Other languages

English (en)

Croatian (hr)

Inventor

Chen Zhaogen

Hamdouchi Hamdouchi Chafiq

James Hembre Erik

Arthur Hipskind Philip

Kenneth Myers Jason

Takakuwa Takako

Lee Toth James

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-20

Filing date

2007-09-17

Publication date

2010-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100516(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-09-17 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

2010-10-31 Publication of HRP20100516T1 publication Critical patent/HRP20100516T1/hr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HR20100516T 2006-09-20 2007-09-17 Tiazolpirazolopirimidini kao antagonisti receptora crf1 HRP20100516T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82626406P	2006-09-20	2006-09-20
PCT/US2007/078605 WO2008036579A1 (en)	2006-09-20	2007-09-17	Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Publications (1)

Publication Number	Publication Date
HRP20100516T1 true HRP20100516T1 (hr)	2010-10-31

Family

ID=38924802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20100516T HRP20100516T1 (hr)	2006-09-20	2007-09-17	Tiazolpirazolopirimidini kao antagonisti receptora crf1

Country Status (33)

Country	Link
US (1)	US8030304B2 (pt)
EP (1)	EP2094709B1 (pt)
JP (1)	JP5161226B2 (pt)
KR (1)	KR101088239B1 (pt)
CN (1)	CN101516887B (pt)
AR (1)	AR062886A1 (pt)
AT (1)	ATE481405T1 (pt)
AU (1)	AU2007297421B2 (pt)
BR (1)	BRPI0717023B8 (pt)
CA (1)	CA2663511C (pt)
CL (1)	CL2007002693A1 (pt)
CR (1)	CR10682A (pt)
CY (1)	CY1110854T1 (pt)
DE (1)	DE602007009305D1 (pt)
DK (1)	DK2094709T3 (pt)
EA (1)	EA015179B1 (pt)
ES (1)	ES2350282T3 (pt)
HR (1)	HRP20100516T1 (pt)
IL (1)	IL197614A (pt)
MA (1)	MA30798B1 (pt)
MX (1)	MX2009003125A (pt)
MY (1)	MY146388A (pt)
NO (1)	NO20091489L (pt)
NZ (1)	NZ575572A (pt)
PE (1)	PE20081377A1 (pt)
PL (1)	PL2094709T3 (pt)
PT (1)	PT2094709E (pt)
RS (1)	RS51545B (pt)
SI (1)	SI2094709T1 (pt)
TN (1)	TN2009000095A1 (pt)
TW (1)	TWI402269B (pt)
UA (1)	UA96458C2 (pt)
WO (1)	WO2008036579A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TWI432435B (zh)	2008-10-02	2014-04-01	Lilly Co Eli	作為合成中間物之噻唑基－吡唑并嘧啶化合物及相關合成方法
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6585625B2 (ja) *	2014-01-21	2019-10-02	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト
PL236355B1 (pl) *	2015-04-02	2021-01-11	Celon Pharma Spolka Akcyjna	Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
KR102571296B1 (ko)	2016-09-07	2023-08-28	더 리전트 오브 더 유니버시티 오브 캘리포니아	P-tau를 감소시키고 인지를 개선하는 알로스테릭 코르티코트로핀-방출 인자 수용체 1 (crfr1) 길항제
KR20250022913A (ko)	2017-08-14	2025-02-17	스프루스 바이오사이언시스 인코포레이티드	코티코트로핀 방출 인자 수용체 길항제
MX2019015318A (es) *	2017-08-14	2020-07-20	Spruce Biosciences Inc	Antagonistas del receptor del factor liberador de corticotropina.
CN112423747A (zh)	2018-04-27	2021-02-26	云杉生物科学公司	用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
CN109134481B (zh) *	2018-08-07	2021-05-14	中山大学	一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) *	2018-09-04	2020-12-21	美商美國禮來大藥廠	2,6-二胺基吡啶化合物
MA54395A (fr)	2018-12-07	2022-03-16	Neurocrine Biosciences Inc	Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
TW202116324A (zh) *	2019-07-19	2021-05-01	美商雲杉生物科技股份有限公司	治療先天性腎上腺增生之方法
CN114502162B (zh)	2019-09-27	2025-03-28	纽罗克里生物科学有限公司	Crf受体拮抗剂及使用方法
US20230065034A1 (en) *	2019-12-04	2023-03-02	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods of use
GR1010096B (el) *	2020-07-02	2021-10-08	Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε,	Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
MX2023001688A (es) *	2020-08-12	2023-02-22	Spruce Biosciences Inc	Metodos y composiciones para tratar el sindrome de ovario poliquistico.
US20240024330A1 (en)	2020-08-26	2024-01-25	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods of use
IL305952A (en)	2021-03-19	2023-11-01	Crinetics Pharmaceuticals Inc	Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023091684A1 (en) *	2021-11-19	2023-05-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023163945A1 (en) *	2022-02-23	2023-08-31	Crinetics Pharmaceuticals, Inc.	Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
WO2025188842A1 (en) *	2024-03-08	2025-09-12	Spruce Biosciences, Inc.	Amorphous solid dispersion of tildacerfont formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2128544T3 (es)	1992-12-17	1999-05-16	Pfizer	Pirrolopirimidinas como antagonistas del crf.
WO1997029109A1 (en) *	1996-02-07	1997-08-14	Janssen Pharmaceutica N.V.	Pyrazolopyrimidines as crf receptor antagonists
CZ299451B6 (cs) *	1996-07-24	2008-07-30	Bristol-Myers Squibb Pharma Company	[1,5-a]-Pyrazolo-1,3,5- triaziny jejich použití afarmaceutické kompozice na jejich bázi
HU229024B1 (en)	1996-07-24	2013-07-29	Bristol Myers Squibb Pharma Co	Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
TR199900389T2 (xx)	1996-08-28	2000-06-21	Pfizer Inc.	�kame edilmi� 6,5-hetero-bisiklik t�revleri.
EP1040831A3 (en) *	1999-04-02	2003-05-02	Pfizer Products Inc.	Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU4203500A (en) *	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
YU23602A (sh)	1999-09-30	2004-09-03	Neurogen Corporation	Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
JP4549630B2 (ja)	2001-03-13	2010-09-22	ブリストル−マイヤーズスクイブファーマカンパニー	コルチコトロピン放出因子受容体リガンドとしての、４−（２−ブチルアミノ）−２，７−ジメチル−８−（２−メチル−６−メトキシピリド−３−イル）ピラゾロ−［１，５−ａ］−１，３，５−トリアジン、その鏡像異性体および薬学的に許容できる塩類
NZ547990A (en) *	2003-12-22	2010-04-30	Smithkline Beecham Cork Ltd	CRF receptor antagonists and methods relating thereto

2007
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/en not_active Ceased
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/sr unknown
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-17 EP EP07842582A patent/EP2094709B1/en active Active
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-17 CA CA2663511A patent/CA2663511C/en active Active
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active Expired - Fee Related
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
2010
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown

Also Published As

Publication number	Publication date
SI2094709T1 (sl)	2011-01-31
AR062886A1 (es)	2008-12-10
EP2094709A1 (en)	2009-09-02
JP5161226B2 (ja)	2013-03-13
NO20091489L (no)	2009-04-16
BRPI0717023B8 (pt)	2021-05-25
TWI402269B (zh)	2013-07-21
DE602007009305D1 (de)	2010-10-28
TN2009000095A1 (en)	2010-08-19
KR20090052366A (ko)	2009-05-25
EA200970303A1 (ru)	2009-10-30
CY1110854T1 (el)	2015-06-10
EP2094709B1 (en)	2010-09-15
PL2094709T3 (pl)	2011-02-28
WO2008036579A1 (en)	2008-03-27
MY146388A (en)	2012-08-15
JP2010504344A (ja)	2010-02-12
IL197614A0 (en)	2009-12-24
PE20081377A1 (es)	2008-09-18
NZ575572A (en)	2011-10-28
CL2007002693A1 (es)	2008-04-18
IL197614A (en)	2012-10-31
HK1132505A1 (en)	2010-02-26
KR101088239B1 (ko)	2011-11-30
CA2663511C (en)	2012-12-04
BRPI0717023A2 (pt)	2014-03-11
AU2007297421B2 (en)	2012-03-08
MA30798B1 (fr)	2009-10-01
UA96458C2 (ru)	2011-11-10
CR10682A (es)	2009-08-13
MX2009003125A (es)	2009-05-28
AU2007297421A1 (en)	2008-03-27
DK2094709T3 (da)	2010-12-06
EA015179B1 (ru)	2011-06-30
RS51545B (sr)	2011-06-30
US20100222339A1 (en)	2010-09-02
US8030304B2 (en)	2011-10-04
BRPI0717023B1 (pt)	2019-11-19
TW200821312A (en)	2008-05-16
CA2663511A1 (en)	2008-03-27
ES2350282T3 (es)	2011-01-20
CN101516887B (zh)	2011-11-02
PT2094709E (pt)	2010-10-04
ATE481405T1 (de)	2010-10-15
CN101516887A (zh)	2009-08-26

Publication	Publication Date	Title
CN116669738B (zh)	2026-04-03	一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途
HRP20200624T1 (hr)	2020-07-10	Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka
AR062886A1 (es)	2008-12-10	Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
JP5323095B2 (ja)	2013-10-23	ピロロ［２，３−ｄ］ピリミジンおよびそのチロシンキナーゼ阻害剤としての使用
JP2010504344A5 (pt)	2010-10-28
RU2015154676A (ru)	2017-07-28	Соединения для лечения спинальной мышечной атрофии
JP5091944B2 (ja)	2012-12-05	イミダゾ［１，２−ｂ］ピリダジン、その調製方法及びＧＡＢＡ受容体リガンドとしてのその使用
JP2019535664A5 (pt)	2020-10-15
RU2009136299A (ru)	2011-04-10	Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида
HRP20180746T4 (hr)	2020-02-21	Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze
CN114599361A (zh)	2022-06-07	Prmt5抑制剂的药物组合物
NZ600229A (en)	2014-06-27	Triazolopyridines
JP2007523151A5 (pt)	2008-02-28
IL210071A (en)	2016-02-29	Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation
PE20120814A1 (es)	2012-07-26	Compuestos y composiciones como inhibidores de la proteina cinasa
JP2009529047A5 (pt)	2010-04-30
PE20091819A1 (es)	2009-12-12	DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA
JP2008509187A5 (pt)	2008-10-02
NO20081924L (no)	2008-05-22	7-[2-[4-(6-fluor-3-metyl-1,2-benzisoksazol-5-yl)-1-pipera-zinyl]etyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amin
JP2013542963A5 (pt)	2015-01-08
PE20090944A1 (es)	2009-08-09	PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
RU2005136166A (ru)	2006-06-10	2-алкинил -и 2-алкенил-пиразол-[4, 3-е]-1. 2. 4-триазоло-[1. 5-с]-пиримидиновые антагонисты а рецептора аденозина
JP2023537630A5 (pt)	2024-08-21
FI3894411T3 (fi)	2024-08-15	7-fenoksi-n-(3-atsabisyklo[3.2.1]oktan-8-yyli)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triatsoli-2-amiinijohdannaisia ja niihin liittyviä yhdisteitä gammasekretaasin modulaattoreina alzheimerin taudin hoitoon
TW200745130A (en)	2007-12-16	2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists